BHB299 / BigHat Biosci - LARVOL DELTA

BHB299: An AI/ML-optimized high avidity/low affinity CEACAM6-directed T cell engager for diverse solid tumors (AACR 2026) - "BHB299 is a first-in-class CEACAM6-directed bispecific T cell engager for the treatment of diverse solid tumors, potentially up to 10% of all new cancers in the US each year. The molecule was engineered on BigHat Biosciences's AI/ML-powered antibody design platform to maximise tumor-specific target engagement. First-in-human studies are supported by the preclinical data package and are planned for 2026."

First-in-human • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM6